Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 4Breast Neoplasms 3Melanoma 2Colorectal Neoplasms 2Untreated Resectable Pancreatic Adenocarcinoma 1Resectable Localized Prostate Cancer 1Prostatic Neoplasms 1Prostate Cancer Recurrent 1Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasms 1Neoplasm, Residual 1Liver Neoplasms 1Klatskin Tumor 1Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1Glioma 1Gastrointestinal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

durvalumab 13Bevacizumab 11Nivolumab 10tremelimumab 7pembrolizumab 6lenvatinib 6fludarabine 6Cyclophosphamide 6atezolizumab 4Radiosurgery 4Cisplatin 4toripalimab 3relatlimab 3Magnetic Resonance Imaging 3Ipilimumab 3Gemcitabine 3X-Rays 2Standard of Care 2Sorafenib 2Riluzole 2Radiotherapy 2Photons 2Patient Navigation 2Lidocaine 2Hepatectomy 2Dexamethasone 2Biopsy 2trastuzumab deruxtecan 1tocilizumab 1tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Neoplasms × Hydroxychloroquine × 1 year × Clear all
NCT03037437 2025-09-04

Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer

The University of Texas Health Science Center at San Antonio

Phase 2 Completed
64 enrolled
Gastrointestinal

Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡